Compared with the simultaneous overexpression of miR-624 and ARRDC3, additional treatment with increased YAP expression could elevate HIF1α, VEGF, and Survivin expression (Figure 4(f,g)), boost resistance of ESCC cells to PT and CIS (Figure 4(h)), facilitate cell proliferation and invasion, and inhibit cell apoptosis in cells treated with 1 ng/mL PT (Figure 4(i-k)). The gene discussed is BIRC5; the disease is in situ carcinoma.